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group, mail-order pharmacy users demonstrated a significantly higher PDC (0.68
vs. 0.61; P0.001) throughout the benefit year. More patients in the mail-order
pharmacy group (49.7%) were adherent with their oral antidiabetic medications
compared to 42.8% in the retail pharmacy group. CONCLUSIONS: Adherence with
oral anti-diabetic medications among Medicare Part D beneficiaries is suboptimal.
Patients using mail-order pharmacy were likely to have better adherence than
those who used retail pharmacies for their medication refills. The causal relation-
ship betweenmail-order pharmacy use and adherence, however, should be further
examined in a randomized study setting.
PDB38
A COMPARISON OF INSULIN ADHERENCE IN PATIENTS WITH TYPE-2 DIABETES
INITIATING THERAPY WITH INSULIN DETEMIR FLEXPEN® OR NPH INSULIN IN
A VIAL
Buysman E1, Conner C2, Liu F1, Aagren M3, Bouchard J4
1i3 Innovus, Eden Prairie, MN, USA, 2Novo Nordisk, Inc., Redmond, WA, USA, 3Novo Nordisk,
Inc., Princeton, NJ, USA, 4Novo Nordisk, Inc., Plaistow, NH, USA
OBJECTIVES: Non-adherence to insulin therapy in patients with type 2 diabetes
presents a serious challenge. Potential explanations for non adherence may in-
clude aversion to insulin self-injection and fear of hypoglycemic events. In clinical
trails, insulin analogs have shown to reduce the risk of hypoglycemic events versus
human insulins, and a recent review suggests that insulin delivered via a pen
device may result in greater adherence versus vial and syringe. This study was
conducted to compare the adherence rates of patients initiating basal insulin ther-
apy with insulin detemir (IDet) FlexPen® versus those initiating basal insulin ther-
apy with NPH via vial and syringe.METHODS: Data were gathered from a large US
national payer retrospective claims database, and included only patients with type
2 diabetes that initiated basal insulin therapy with either IDet FlexPen® or NPH in
vials. Patientswith claims for any other type of insulin, other than the index insulin
formulations during the 12-month observation period were excluded. Patients
were defined as being adherent to therapy if they had a medication possession
ration (MPR) of at least 0.80 in the 12-month follow up period. RESULTS: The IDet
FlexPen® cohort (n1082) and the NPH vial cohort (n794) were of similar age
(54.06 vs. 53.13, p0.134); however, the IDet FlexPen® cohort had a lower propor-
tion of female patients (44% vs. 55%, p0.001) and fewer patients without a history
of pre-index OADs (9% vs 45%, p0.001), than the NPH vial cohort. After controlling
for important confounders, patients initiating insulin therapy with IDet FlexPen®
were 39%more likely to achieve anMPR of 0.80 or greater versus patients initiating
insulin therapy with NPH vial (95% CI: 1.04-1.85). CONCLUSIONS: These results
suggest that adherence may be improved for patients initiating basal insulin ther-
apy with IDet in the FlexPen® versus NPH in a vial.
PDB39
A DESCRIPTIVE ANALYSIS OF TREATMENT ADHERENCE WITH GROWTH
HORMONE: FINDINGS FROM A NATIONAL MANAGED CARE POPULATION IN
THE UNITED STATES
Fincher C1, Kozma C2, Meletiche DM3, Velez F3
1EMD Serono, Inc., Ann Arbor, MI, USA, 2Independent Research Consultant/Adjunct Professor,
University of South Carolina, St. Helena Island, SC, USA, 3EMD Serono, Inc., Rockland, MA, USA
OBJECTIVES: To describe adherence with growth hormone (GH) treatment by age
group among newly initiated patients. METHODS: Somatropin pharmacy claims
were selected from July 1999 throughMay 2008 in PharMetrics, a nationalmanaged
care dataset. Continuous eligibility for 6 months before and 12 months after the
first GH prescription (i.e., index date) was required. Patients were excluded if they
had: claims for brands of somatropin used for HIV-associated wasting; potential
data entry errors in key variables; or had a claim for GH product no longer on the
market. Adherence was assessed using medication possession ratios (MPRs) de-
fined as the sum of days supply divided by 360 days of observation and capped at
100%. Evaluations by age group included average MPR, percentage of patients with
at least 80%MPR, and percentage of patients who stay on therapy (i.e., persistence)
for at least 80% of the observation period. RESULTS: A total of 1355 patients receiv-
ing GH met study criteria; 64.0% males and 36.0% females. The percentage of pa-
tients receiving GH by age category was as follows:4 (5.2%), 4 to13 (40.9%), 13 to
18 (34.8%), 18 (19.1%). Average MPR was greatest in the 4 age group (87.2; SE
2.8), followed by 4 to13 (82.9; SE 1.0), 13 to18 (80.5; SE 1.1) and 18 (68.1; SE 1.5).
Patients in the 18 groups had significantly lower mean MPR (68.1% SD 27.2) than
all other age groups (all above 80%; p0.0001). The percentage of patients with an
MPR of at least 80%was 71.4%, 69.3%, 66.1% and 44.8%, respectively. Approximately
89% of the 4 to 13 age group remained on therapy (i.e., persisted) for more than
80% of the observation period versus only 64.5% of the 18 group. CONCLUSIONS:
Adherence with growth hormone decreases as age increases. There is opportunity,
however, for improvement in all age groups.
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OBJECTIVES: To examine adherence to medications used in managing painful di-
abetic peripheral neuropathy (PDPN) and determine their association with oral
antidiabetic medication (OAD) adherence.METHODS: A retrospective cohort anal-
ysis using the Texas Medicaid prescription claims database. Study participants
were adult (30-64 years) Medicaid beneficiaries prescribed OAD and PDPNmedica-
tions. Data were extracted from June 1, 2003 to October 31, 2009. The study’s re-
search objectiveswere to: 1) provide a description of PDPNandOADmedication use
among the study subjects; 2) determine if PDPN medication adherence differs
among individual PDPN medication (i.e., TCAs, gabapentin, pregabalin and dulox-
etine); and 3) determine if PDPNmedication adherence is related to post-indexOAD
medication adherence while controlling for covariates. Adherence was measured
usingmedication possession ratio (MPR). RESULTS:A total of 4277 patientsmet the
study’s inclusion criteria. The overall mean MPR (SD) for PDPN medications was
75.4% (23.9%). Mean MPR differed significantly among individual PDPN medica-
tions (p0.0001). Mean MPR was highest for duloxetine (85.6%18.2%) and was
lowest for pregabalin (69.4%24.9%). The overall mean MPR (SD) for OAD medi-
cations decreased significantly (p0.0001) from 73.0% (24.3%) in the pre-index
period to 64.5% (25.6%) in the post-index period. After controlling for covariates,
non-adherers (i.e., MPR80%) to PDPN medications, compared to adherers (i.e.,
MPR80%), were significantly less likely to be adherent to OADmedications [Odds
Ratio (OR) 0.626; 95% CI0.545-0.719]. CONCLUSIONS: Patients’ adherence to
PDPN medications was associated with adherence to OAD medications. Patients
whowere adherent to PDPNmedicationsweremore adherent to OADmedications.
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OBJECTIVES: To determine treatment gap trends among first time GH recipients
using a large, USmanaged care database. To our knowledge, this is the first analysis
of gaps in GH treatment using a large sample of prescription claims. METHODS:
Somatropin pharmacy claims were selected from July 1999 through May 2008 in
PharMetrics, a national managed care dataset. Continuous eligibility for 6 months
before and 12 months after the first GH prescription (i.e., index date) was required.
Patients were excluded if they had: claims for brands of somatropin approved for
human immunodeficiency virus-associated wasting and short bowel syndrome in
patients receiving specialized nutritional support, potential data entry errors in
days supply, quantity dispensed or allowed amounts, had a claim for GH product
no longer on themarket, or incorrect doses based on data entry errors. The number
and percentage of patients with treatment gaps of at least 60 days were based on
reported days supply dispensing dates. RESULTS: A total of 1355 patients receiving
GH met study criteria. The study population consisted of 64.0% males and 36.0%
females. The percentage of patients receiving GH by age category were as follows:
4 (5.2%), 4 to13 (40.9%), 13 to18 (34.8%), 18 (19.1%). Gaps in therapy of 60 days
were calculated and results showed that 27.0% of GH patients discontinued their
medication for at least 60 days within 1 year of follow-up. CONCLUSIONS: Gaps in
therapy occur among approximately 27% of GH users during a one-year time pe-
riod, regardless of age or gender. Reasons for this therapeutic gap remain un-
known.
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BACKGROUND: Evidence regarding the value and utility of SMBG in insulin-naïve
type 2 diabetes (T2DM) has beenmixed. Failure to personally understand the value
associated with SMBG results and/or share SMBG data with healthcare providers
(HCPs) may contribute to poor treatment adherence. The Structured Testing Pro-
gram (STeP) study, a prospective, cluster-randomized,multi-centered clinical trial,
demonstrated that structured SMBG significantly improves glycemic control and
quality of life in non-insulin-treated T2DM. In the study, 483 poorly-controlled
(HbA1c 7.5%), insulin-naïve T2DM patients were randomized to structured test-
ing (STG) or active control (ACG). All STG and ACG patients received free blood
glucose meters and test strips. STG subjects also used the ACCU-CHEK® 360 View
Blood Glucose Analysis System (”tool”) quarterly to collect/interpret 7-point glu-
cose profiles over 3 consecutive days. STG patients then brought the tool to their
HCPs. OBJECTIVES: To evaluate STeP study patient perceptions regarding diabetes
self-management and interactionswithHCPs.METHODS:Aqualitative descriptive
design; data were collected via phone interviews with 59 (20 ACG, 39 STG) STeP
study participants. Data were analyzed using a content analysis approach.
RESULTS: Sample characteristics included: 54% male; 56% White; mean age 57.1
years; 49% some college or more; mean duration of T2DM 7.4 years; and mean
baseline HbA1c 8.9%. Although participants from both study arms perceived SMBG
as having personal value, STG patients reported additional benefits of using the
tool, including: more in-depth understanding of diabetes; increased confidence in
daily decision-making; more meaningful discussions with HCPs; and shared deci-
sion-making regarding treatment. CONCLUSIONS:Our findings suggest that use of
structured testing, as part of a comprehensive intervention where patients and
HCPs collaborate to gather, interpret and utilize SMBG data, promotes a positive
change in how patients view SMBG, improves patient comprehension of diabetes
and diabetes self-management, and increases patient participation in their treat-
ment regimens.
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OBJECTIVES: Diabetes has been increasing worldwide and the treatment of type 2
diabetes is based on lifestylemodification and pharmacological therapy. Appropri-
ate self-care practices including lifestylemodifications andmedication compliance
are critical to satisfactory control andmanage diabetes and to prevent from comor-
bidities. The objective of this studywas to assess current treatment patterns, treat-
ment compliance and reasons for noncompliance for patients with type 2 diabetes
in Pakistan. METHODS: A cross-sectional study was conducted to collect data
through structured interviews based on pre-tested questionnaire. Total 211 pa-
tients including 46% males and 54% females from the ages 25 and over were ran-
domly selected for the study fromapopulation of patients attending 5 primary care
diabetes centers throughout Karachi. Information was collected on socio-demo-
graphic characteristics, diabetes duration and compliance to physician’s advices.
RESULTS: Overall, median age for male subjects was 53 years, significantly older
(p0.008) than females (46 years). The mean duration of diabetes among respon-
dents was 9.23.8 years. Of the total, majority of patients were treated with oral
medication (61%). Only 27% reported full compliance as per physician’s advice for
timelymedication, routine exercise, timely lab investigation and follow up for next
visit. About 45% of the subjects were taking medication for diabetes related com-
plications. Lack of financial resources, knowledge and supportive services and fear
of needle were the main reasons for noncompliance. We also found that people
with low literacy levels were less likely to manage their condition effectively com-
pared to people with higher educational level (p0.001). CONCLUSIONS: To man-
age the diabetes both physicians and patients should attempt to improve compli-
ance, which could lead to better disease management. Based on the findings, a
public health intervention and information campaign is needed to change behav-
iours of persons with diabetes. Further, physicians can also educate patients by
identifying potential risks of non-compliance and educate them accordingly.
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OBJECTIVES: To quantify the influence of methodological assumptions/parame-
ters on the results of prescription-based NA analysis based on 3-years prescription
data (German Statutory Health Insurance Fund) covering 241,537 T2DM patients.
METHODS: With the help of MPRs in an interval-based approach, a NA-base sce-
nario for 25 anti-diabetic active ingredients was calculated for each patient. In a
scenario analysis, the quantitative influence of all in all 9 parameters on the MPR
level was derived. The most important parameter concerned the definition of an
ideal prescription profile (“100%-adherer”). Assumptions simplifying the real pre-
scription behaviour did not allow to accurately reflect the variety of medications
and the clinical need to change medications. Therefore, a total of eight clinically
meaningful prescription profileswere derived assigning patients exclusively by the
use of self-developed algorithms. For each patient a MPR estimated by standard
methodology (base case)was comparedwith theMPR based on our novel approach.
RESULTS: In the base case, the average MPR resulting from the analysed active
ingredient combinations was 80.76%. A total of 62.85% of patients had an
MPR80%. According to the novel prescription profiles, patients were distrib-
uted as follows: 59.9% Mono-medication, 12.9% Single-Drug Switcher, 11.3%
Single-Drug Add-on, 2.0% Multiple-Drug Add-on, 5.0% Polytherapy consistent,
2.5% Polytherapy Add-on, 3.5% Polytherapy Drop-off, and 1.3% Polytherapy
Switcher. A total of 1.6% of the patients could not unequivocally be assigned to
one of the categories. Comparing a base-case MPR analysis with our novel ap-
proach resulted in MPR deviations in specific patient groups of up to 27.4 per-
centage points. CONCLUSIONS: Probably the biggest challenge in NA analysis
based on prescription data is to differentiate between physician-induced and pa-
tient-induced medication changes. The first should be reflected in the adequate
profile of an NA analysis and should not be misinterpreted as NA itself. The meth-
odology described presents a powerful alternative for defining clinically meaning-
ful prescription patterns.
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OBJECTIVES: The burden of diabetic peripheral neuropathic pain (DPNP) on pa-
tients’ lives is poorly understood and insufficiently measured with current instru-
ments. Proper assessment of DPNP impact on patients’ lives is critical to accurately
determine treatment efficacy. METHODS: 45 blinded, semi-structured telephone
interviews were conducted to assess the impact of DPNP on functioning and pa-
tient well-being enrolled in a randomized, double-blind, placebo-controlled study.
Interviews were taped, transcribed, coded, and analyzed according to grounded
theory principles. RESULTS: Patients were 31%female, 53% white and the average
agewas 56 years. Twomajor domains of burdenwere identified: physical function-
ing and daily life. Physical functioning was affected in 36 (80%) patients whose
DPNP led to difficulty in walking, 33 (73%) reported low energy levels, and 32 (71%)
noted a diminished ability to exercise. Twenty-five (55%) patients reported difficul-
ties with bending, 22 (49%) difficulty standing, 20 (44%) reduced ease of movement,
19 (42%) had problems with balance and 16 (36%) in climbing stairs. DPNP affected
sleep in 37 (82%) patients who reported awakening in the night, 28 (62%) had diffi-
culty falling asleep, 16 (36%) couldn’t fall back asleep once awakened; and 36 (80%)
patients rarely felt rested during the day. Daily life was affected in 34 (76%) patients
leading to reduced productivity, 30 (67%) reported that DPNP reduced their enjoy-
ment of life, and 26 (58%) found that DPNP limited their recreational activities.
Twenty-four (53%) of patients had a reduced ability to focus on tasks due to pain, 22
(49%) reported that DPNP limited their ability to work, 20 (44%) experienced diffi-
culty in accomplishing routine household chores, and 17 (38%) had reduced
independence. CONCLUSIONS: DPNP causes significant burden on patient’s phys-
ical functioning and daily life. PROmeasures used to determine treatment efficacy
should assess these impacts to accurately reflect the patient’s perspective.
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OBJECTIVES: Diabetic Peripheral Neuropathic Pain (DPNP) is a poorly understood
complication of diabetes that has serious consequences for patients’ physical func-
tioning and daily activities. Awell-developed patient-reported outcome (PRO)mea-
sure that can assess the impact of DPNP on function and that is sensitive to change
would facilitate research important to patients. The purpose of the study was to
develop a measure of key impacts important to patients with DPNP. METHODS:
Diabetic Peripheral Neuropathic Pain (DPNP) is a poorly understood complication of
diabetes that has serious consequences for patients’ physical functioning and daily
activities. A well-developed patient-reported outcome (PRO) measure that can as-
sess the impact of DPNP on function and that is sensitive to changewould facilitate
research important to patients. The purpose of the studywas to develop ameasure
of key impacts important to patients with DPNP. RESULTS: Saturation of concepts
was reached after 3 focus groups and telephone interviews with a total of 25 DPNP
patients (demographics: average age 52 years old, 68% male, 60% White). The av-
erage duration of DPNPwas 5 years (range 1-20 years) and the average self-reported
pain score (scale 0-10) was 6.9 (range 4-10). The theoretical framework described
two domains of impact: Physical Functioning and Daily Functioning. Based on the
results of the cognitive debriefing a 27-item, validation ready version of the mea-
sure with 4 domains (Physical Functioning–Sleep, Physical Functioning-Mobility,
Daily Functioning- Daily Activities and Daily Functioning-Relationships) was
generated. CONCLUSIONS: The Diabetic Peripheral Neuropathic Pain Impact Mea-
sure is believed to accurately capture relevant DPNP patients’ experiences as it
relates to their ability to function. Data generated from the measure should assist
clinicians in assessing key impacts in patientswithDPNP, facilitate development of
targeted treatments and provide a meaningful measurement of treatment effect.
PDB47
NATIONAL IMPACT OF HEALTH CARE ACCESS ON HEALTH-RELATED QUALITY
OF LIFE OF PATIENTS WITH DIABETES IN THE UNITED STATES
Tundia N, Desai VC, Berry E, Heaton PC
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Lack of access to healthcare for patients with diabetes has been as-
sociatedwith lower self-reported health-related quality of life (HRQOL), whichmay
lead to significant economic burden. The objective of the study was to determine
the impact of healthcare access on HRQOL of patients with diabetes. METHODS:
The 2009 Behavioral Risk Factor Surveillance System (BRFSS), a national health
telephone survey administered by the Centers for Disease Control and Prevention
(CDC), was analyzed. It included questions on patient demographics and health-
related perceptions, conditions, and behaviors. HRQOL was defined as the number
of unhealthy days, a sum of physical and mental unhealthy days in the past one
month. Healthcare access was defined by whether the patient had healthcare cov-
erage, had a healthcare professional or could not see a doctor because of cost.
Descriptive analysis includedmeans, standard errors and relevant T-tests. Poisson
regression was performed to measure the impact of healthcare access variables,
age, race, gender,marital status andmedian household income onunhealthy days.
RESULTS: In 2009, from 5.2 million diabetic patients, 0.7 million (14%) did not have
healthcare coverage, 0.48 million (9%) did not have healthcare professional and
1.54 million (30%) could not see a doctor due to cost. The average number of un-
healthy days in a month, for diabetic patients with healthcare coverage was lower
than those without (22 days versus 23 days, p-value0.01); for those who could see
a doctor due to cost was lower than those who could not (22 days versus 24 days,
p0.01); was the same for those with or without a healthcare professional. Regres-
sion results showed, not having healthcare coverage and healthcare professional,
each significantly (p-value0.01) increased an excess unhealthy day in diabetic
patients. CONCLUSIONS: Lack of healthcare access negatively impacts HRQOL.
Measures are needed to ensure adequate healthcare access in diabetic patients.
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OBJECTIVES: To assess the quality of life (QoL) of Taiwanese type 2 diabetes pa-
tients, we have conducted feasibility studies applying different QoL utility scores.
This study aims to explore the adaptation and feasibility of time-trade-off (TTO)
method for measuring QoL in Taiwanese diabetic outpatients. METHODS: This
cross-sectional study was conducted from June to December 2010 at nephrology
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